IMMUNEONCO-B(01541),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01541 IMMUNEONCO-B

Not Yet Opened 02-05 16:08:28

4.550

+0.390

+9.38%

High4.610	Low4.010	Vol2.00M
Open4.270	D1 Closing4.160	Amplitude14.42%
Mkt Cap1.97B	Tradable Cap1.91B	Total Shares432.00M
T/O8.69M	T/O Rate0.47%	Tradable Shares420.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"IMMUNEONCO-B","latestPrice":4.55,"timestamp":1770278908003,"preClose":4.16,"halted":0,"volume":1995600,"delay":0,"changeRate":0.09374999999999992,"floatShares":420477305,"shares":432000000,"eps":-0.79,"marketStatus":"Not Yet Opened","change":0.39,"latestTime":"02-05 16:08:28","open":4.27,"high":4.61,"low":4.01,"amount":8688740,"amplitude":0.144231,"askPrice":4.59,"askSize":3600,"bidPrice":4.55,"bidSize":800,"shortable":3,"etf":0,"ttmEps":-0.769,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770341400000},"marketStatusCode":0,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":4.16,"openAndCloseTimeList":[[1770255000000,1770264000000],[1770267600000,1770278400000]],"volumeRatio":1.5271358167826643,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01541/wiki","defaultTab":"wiki","newsList":[{"id":"1180124161","title":"IMMUNEONCO-B (01541) Rises Over 5% as Core Product IMM01 Expected to Submit pre-BLA Application by Year-End","url":"https://stock-news.laohu8.com/highlight/detail?id=1180124161","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180124161?lang=en_us&edition=fundamental","pubTime":"2026-01-22 14:58","pubTimestamp":1769065099,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) surged more than 5%. At the time of writing, the stock was up 5.11% to HK$4.94, with a turnover of HK$8.3481 million. On the news front, on the evening of January 21, IMMUNEONCO...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1610","01541","02800"],"gpt_icon":1},{"id":"1172752075","title":"ImmuneOnco (1541) Announces Phase III Clinical Trial Enrollment Progress for Timdarpacept","url":"https://stock-news.laohu8.com/highlight/detail?id=1172752075","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172752075?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:22","pubTimestamp":1768994578,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541) reported that 104 patients had been enrolled by December 31, 2025, in the Phase III trial of IMM01 (Timdarpacept) as a first-line treatment for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"gpt_icon":0},{"id":"1125010183","title":"IMMUNEONCO-B (01541): Business Operations and Clinical Development Maintain Normalcy","url":"https://stock-news.laohu8.com/highlight/detail?id=1125010183","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125010183?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:10","pubTimestamp":1768993827,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) announced the successful completion of patient recruitment for the Phase III clinical trial of IMM01 (Tedaparicep) as a first-line treatment for chronic myelomonocytic leukemia...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2605105702","title":"ImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2605105702","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605105702?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:06","pubTimestamp":1768993579,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals  Co. Ltd. announced the successful completion of enrollment of 104 patients in the Phase III clinical trial of IMM01  for the first-line treatment of chronic myelomonocytic leukemia  as of December 31, 2025. The company expects to complete enrollment of the 132 patients required for interim analysis by the end of March 2026. Results from the trial have not yet been presented. IMM01  in combination with azacitidine received orphan-drug designation from the U.S. Food and Drug Administration in November 2023. The company holds global intellectual property and commercial rights to IMM01 .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals  Co. Ltd. published the original content used ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL5fs9KQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"1107092495","title":"Hong Kong Stock Movement | IMMUNEONCO-B (01541) Surges Over 10% in Morning Trading as IMM01 Receives Approval for Clinical Trial in Atherosclerosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1107092495","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107092495?lang=en_us&edition=fundamental","pubTime":"2026-01-13 11:14","pubTimestamp":1768274065,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) rose over 10% in morning trading. As of the time of writing, the stock was up 8.63%, trading at HKD 6.67, with a turnover of HKD 11.1965 million. The company announced that the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"gpt_icon":0},{"id":"1123079143","title":"IMMUNEONCO-B (01541) Receives NMPA Approval for IMM01 (Tidapaxic) Clinical Trial in Atherosclerosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1123079143","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123079143?lang=en_us&edition=fundamental","pubTime":"2026-01-12 17:28","pubTimestamp":1768210116,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) announced that the group has received approval from the China National Medical Products Administration (NMPA) to conduct a clinical trial for IMM01 (Tidapaxic) for the treatment...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2602159000","title":"ImmuneOnco Biopharmaceuticals Receives NMPA Approval for IMM01 Clinical Trial for Atherosclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2602159000","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602159000?lang=en_us&edition=fundamental","pubTime":"2026-01-12 17:24","pubTimestamp":1768209889,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals  Co. Ltd. announced that it has received approval from the National Medical Products Administration  of China to conduct a clinical trial of its core product, IMM01 , for the treatment of atherosclerosis. IMM01 is an innovative molecule targeting CD47 and is the first SIRPα-Fc fusion protein to enter clinical development for this indication. The company holds global intellectual property and commercial rights for IMM01. The announcement cautioned that there is no guarantee the product will ultimately be successfully developed or marketed. No other beneficiary organizations were mentioned in connection with this regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceutical","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLcVDtW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2602900765","title":"ImmuneOnco Biopharmaceuticals Shanghai - Approval by Nmpa China for Clinical Trial of Imm01 (Timdarpacept) for Atherosclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2602900765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602900765?lang=en_us&edition=fundamental","pubTime":"2026-01-12 17:24","pubTimestamp":1768209854,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YA1UE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"1173167885","title":"Guoyuan International: IMMUNEONCO-B (01541) Regains Global Rights to IMM2510, Overseas R&D Expected to Accelerate","url":"https://stock-news.laohu8.com/highlight/detail?id=1173167885","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173167885?lang=en_us&edition=fundamental","pubTime":"2026-01-08 17:11","pubTimestamp":1767863477,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) has regained the global rights to IMM2510 and IMM27M, allowing the company to reassume leadership over its overseas clinical development, which is expected to accelerate its...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2601828584","title":"ImmuneOnco Regains Global Rights to Two Anti-tumor Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2601828584","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601828584?lang=en_us&edition=fundamental","pubTime":"2026-01-07 10:39","pubTimestamp":1767753585,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals   regained the global rights to IMM2510 and IMM27M after terminating a license agreement with Axion Bio, according to a Hong Kong bourse filing Tuesday.Shares of the firm fell nearly 1% in morning trade Wednesday.The termination does not affect the $35 million ImmuneOnco received as upfront and milestone payment from Axion, the firm said.Both drug candidates were being developed as anti-tumor medicines.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01541","BK1161","MDCO"],"gpt_icon":0},{"id":"2601824543","title":"While institutions invested in ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541) benefited from last week's 10% gain, individual investors stood to gain the most","url":"https://stock-news.laohu8.com/highlight/detail?id=2601824543","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601824543?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:08","pubTimestamp":1767748123,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by individual investors in ImmuneOnco Biopharmaceuticals (Shanghai) indicates...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1541/immuneonco-biopharmaceuticals-shanghai-shares/news/while-institutions-invested-in-immuneonco-biopharmaceuticals","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1541/immuneonco-biopharmaceuticals-shanghai-shares/news/while-institutions-invested-in-immuneonco-biopharmaceuticals","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"1153516914","title":"Recovering Overseas Rights, IMMUNEONCO-B (01541) Strategic Adjustment Opens New Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=1153516914","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153516914?lang=en_us&edition=fundamental","pubTime":"2026-01-07 08:02","pubTimestamp":1767744156,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) announced after yesterday's market close that it has reclaimed the global rights (excluding Greater China) for IMM2510 (PD-L1/VEGF) and IMM27M (CTLA-4 ADCC+) from Instil Bio,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2601172892","title":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Says Immuneonco To Regain Global Rights- To IMM2510, IMM27M","url":"https://stock-news.laohu8.com/highlight/detail?id=2601172892","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601172892?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:43","pubTimestamp":1767703399,"startTime":"0","endTime":"0","summary":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Says Immuneonco To Regain Global Rights- To IMM2510, IMM27MJan 6  - ImmuneOnco Biopharmaceuticals Shanghai Inc 1541.HK:IMMUNEONCO TO REGAIN GLOBAL RIGHTS- TO IMM2510 AND IMM27MFurther company coverage: 1541.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y70BY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"gpt_icon":0},{"id":"1177949427","title":"IMMUNEONCO-B (01541) Regains Global Rights to IMM2510 and IMM27M","url":"https://stock-news.laohu8.com/highlight/detail?id=1177949427","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177949427?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:12","pubTimestamp":1767701521,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) announced that, according to the licensing and collaboration agreement, the company had agreed to grant Axion exclusive rights to research, develop, and commercialize certain...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2601894377","title":"ImmuneOnco Biopharmaceuticals Shanghai Inc - ImmuneOnco to Regain Global Rights- to Imm2510 and Imm27m","url":"https://stock-news.laohu8.com/highlight/detail?id=2601894377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601894377?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:01","pubTimestamp":1767700888,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y70BY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"1142602958","title":"HK Stock Movement | IMMUNEONCO-B (01541) Rises Nearly 4% as IND Application for Self-Developed Amurelifusp-α Subcutaneous Formulation IMM0306S Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1142602958","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142602958?lang=en_us&edition=fundamental","pubTime":"2025-12-19 14:36","pubTimestamp":1766126180,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) rose nearly 4%, reaching HK$6.23 by the time of writing, with a trading volume of HK$3.12 million. The company announced on December 18 that the Investigational New Drug (IND)...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"gpt_icon":0},{"id":"1173544573","title":"ImmuneOnco (01541) Announces Registered Share Capital Increase as of November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1173544573","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173544573?lang=en_us&edition=fundamental","pubTime":"2025-12-04 17:03","pubTimestamp":1764839025,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (stock code: 01541) published a monthly return indicating a rise in registered share capital to RMB 420,477,305 for its H shares, from 396,277,305 in the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"gpt_icon":0},{"id":"2588743670","title":"ImmuneOnco Biopharmaceuticals Chairman/CEO Boosts Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2588743670","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588743670?lang=en_us&edition=fundamental","pubTime":"2025-12-04 10:48","pubTimestamp":1764816526,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals  said Chairman and Chief Executive Tian Wenzhi purchased 50,000 H shares on Dec. 3 at an average price of HK$6.6258, according to a Wednesday Hong Kong bourse filing.Shares of the firm were up over 3% in Thursday morning trade.The purchase lifted Tian's stake to over 116.1 million shares, or 26.91% of the company's issued capital.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"1154296209","title":"ImmuneOnco (1541 HK) Announces Chairman’s Shareholding Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=1154296209","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154296209?lang=en_us&edition=fundamental","pubTime":"2025-12-03 18:24","pubTimestamp":1764757455,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “Company”) reported that its Executive Director, Chief Executive Officer, and Chairman of the Board, Dr. Tian Wenzhi, acquired 50,000 H shares in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"gpt_icon":0},{"id":"2588017381","title":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Inc Says CEO Purchases 50,000 H Shares At Average Price Of HK$6.6258 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2588017381","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588017381?lang=en_us&edition=fundamental","pubTime":"2025-12-03 18:10","pubTimestamp":1764756637,"startTime":"0","endTime":"0","summary":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Inc Says CEO Purchases 50,000 H Shares At Average Price Of HK$6.6258 EachDec 3  - ImmuneOnco Biopharmaceuticals Shanghai Inc 1541.HK:CEO PURCHASES 50,000 H SHARES AT AVERAGE PRICE OF HK$6.6258 EACHFurther company coverage: 1541.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X817A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Inc Says CEO Purchases 50,000 H Shares At Average Price Of HK$6.6258 Each","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"gpt_icon":0}],"profile":{"websiteUrl":"http://immuneonco.com","stockEarnings":[{"period":"1week","weight":-0.0257},{"period":"1month","weight":-0.3053},{"period":"3month","weight":-0.4241},{"period":"6month","weight":-0.5886},{"period":"1year","weight":-0.0421},{"period":"ytd","weight":-0.2196}],"compareEarnings":[{"period":"1week","weight":-0.0387},{"period":"1month","weight":0.0065},{"period":"3month","weight":0.0245},{"period":"6month","weight":0.0815},{"period":"1year","weight":0.3053},{"period":"ytd","weight":0.049}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"ImmuneOnco Biopharmaceuticals Shanghai Inc is a China-based company mainly engaged in the development of tumor immunotherapy. The Company's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The Company's core product IMM01 is an innovative CD47-targeted molecule. The Company mainly operates its businesses in the domestic and overseas markets.","exchange":"SEHK","name":"IMMUNEONCO-B","nameEN":"IMMUNEONCO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IMMUNEONCO-B(01541),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IMMUNEONCO-B(01541) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IMMUNEONCO-B,01541,IMMUNEONCO-B股票,IMMUNEONCO-B股票老虎,IMMUNEONCO-B股票老虎国际,IMMUNEONCO-B行情,IMMUNEONCO-B股票行情,IMMUNEONCO-B股价,IMMUNEONCO-B股市,IMMUNEONCO-B股票价格,IMMUNEONCO-B股票交易,IMMUNEONCO-B股票购买,IMMUNEONCO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IMMUNEONCO-B(01541),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IMMUNEONCO-B(01541) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}